Abstract：
BACKGROUND: When lung cancer is combined with concurrent tuberculosis (TB), it increases the difficulty of diagnosis and treatment, leading to missed and/or misdiagnosed cases.
OBJECTIVE: To provide reference markers for the clinical diagnosis of patients with lung cancer complicated by active pulmonary TB (APT).
METHODS: The concentration of survivin in diseased tissue, and miR-29a and IGRAs interferon gamma (IFN-γ) in serum were evaluated in 25 patients with non-small cell lung carcinoma (NSCLC) complicated by APT, 32 patients with NSCLC and 30 patients with APT.
RESULTS: The expression of miR-29a in serum of patients with APT was higher than in patients with NSCLC complicated by APT (least significant difference (LSD)-t = 4.724, p < 0.001), and the NSCLC group (LSD-t = 6.619, p < 0.001). Furthermore, patients with NSCLC complicated by APT had higher miR-29a concentration than the NSCLC group. The rate of positive survivin expression in NSCLC (χ2 = 23.418, p < 0.001) and NSCLC combined with APT group (χ2 = 17.160, p < 0.001) was significantly higher than in patients with APT. The concentration of IFN-γ in serum of the NSCLC complicated by APT group (LSD-t = 2.912, p = 0.004) and the APT group (LSD-t = 4.452, p < 0.001) was higher than in the NSCLC group. The level of IFN-γ in serum of the NSCLC complicated by APT group were higher than in the APT group, but there was no statistical difference.
CONCLUSIONS: The levels of MiR-29a, Survivin and IFN-γ was helpful for differential diagnosis of lung cancer and tuberculosis.
OBJECTIVE: To provide reference markers for the clinical diagnosis of patients with lung cancer complicated by active pulmonary TB (APT).
METHODS: The concentration of survivin in diseased tissue, and miR-29a and IGRAs interferon gamma (IFN-γ) in serum were evaluated in 25 patients with non-small cell lung carcinoma (NSCLC) complicated by APT, 32 patients with NSCLC and 30 patients with APT.
RESULTS: The expression of miR-29a in serum of patients with APT was higher than in patients with NSCLC complicated by APT (least significant difference (LSD)-t = 4.724, p < 0.001), and the NSCLC group (LSD-t = 6.619, p < 0.001). Furthermore, patients with NSCLC complicated by APT had higher miR-29a concentration than the NSCLC group. The rate of positive survivin expression in NSCLC (χ2 = 23.418, p < 0.001) and NSCLC combined with APT group (χ2 = 17.160, p < 0.001) was significantly higher than in patients with APT. The concentration of IFN-γ in serum of the NSCLC complicated by APT group (LSD-t = 2.912, p = 0.004) and the APT group (LSD-t = 4.452, p < 0.001) was higher than in the NSCLC group. The level of IFN-γ in serum of the NSCLC complicated by APT group were higher than in the APT group, but there was no statistical difference.
CONCLUSIONS: The levels of MiR-29a, Survivin and IFN-γ was helpful for differential diagnosis of lung cancer and tuberculosis.
摘要：
背景：当肺癌合并并发结核病（TB）时，它增加了诊断和治疗的难度，导致漏诊和/或误诊病例。
目的：为肺癌合并活动性肺结核(APT)患者的临床诊断提供参考指标。
方法：患病组织中存活素的浓度，检测25例非小细胞肺癌(NSCLC)合并APT患者血清miR-29a和IGRAs干扰素γ(IFN-γ)水平,NSCLC患者32例，APT患者30例。
结果：APT患者血清中miR-29a的表达高于NSCLC合并APT患者（最小差异（LSD）-t=4.724，p<0.001），和NSCLC组（LSD-t=6.619，p<0.001）。此外，伴有APT的NSCLC患者的miR-29a浓度高于NSCLC组.Survivin在NSCLC(χ2=23.418,p<0.001)和NSCLC合并APT组(χ2=17.160,p<0.001)中的阳性表达率明显高于APT组。NSCLC合并APT组(LSD-t=2.912,p=0.004)和APT组(LSD-t=4.452,p<0.001)血清IFN-γ浓度高于NSCLC组。NSCLC合并APT组血清IFN-γ水平高于APT组,但没有统计学差异。
结论：MiR-29a的水平，Survivin和IFN-γ有助于肺癌和肺结核的鉴别诊断。
目的：为肺癌合并活动性肺结核(APT)患者的临床诊断提供参考指标。
方法：患病组织中存活素的浓度，检测25例非小细胞肺癌(NSCLC)合并APT患者血清miR-29a和IGRAs干扰素γ(IFN-γ)水平,NSCLC患者32例，APT患者30例。
结果：APT患者血清中miR-29a的表达高于NSCLC合并APT患者（最小差异（LSD）-t=4.724，p<0.001），和NSCLC组（LSD-t=6.619，p<0.001）。此外，伴有APT的NSCLC患者的miR-29a浓度高于NSCLC组.Survivin在NSCLC(χ2=23.418,p<0.001)和NSCLC合并APT组(χ2=17.160,p<0.001)中的阳性表达率明显高于APT组。NSCLC合并APT组(LSD-t=2.912,p=0.004)和APT组(LSD-t=4.452,p<0.001)血清IFN-γ浓度高于NSCLC组。NSCLC合并APT组血清IFN-γ水平高于APT组,但没有统计学差异。
结论：MiR-29a的水平，Survivin和IFN-γ有助于肺癌和肺结核的鉴别诊断。
